Tirzepatide vs Semaglutide: The Head-to-Head Trials

Most comparisons on this site have to be assembled from separate studies, because the two compounds were never tested against each other. This one is different, and it is worth knowing why that matters.

Tirzepatide and semaglutide have been compared directly, head to head, in randomized controlled trials. In SURPASS-2 — a Phase 3, multicenter, randomized trial published in The New England Journal of Medicine — tirzepatide was compared against semaglutide once weekly in patients with type 2 diabetes¹. A separate head-to-head program in obesity, SURMOUNT-5, has since produced its own published analyses².

You may know both molecules better by their brand names. Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for weight management; semaglutide is sold as Ozempic for diabetes, Wegovy for weight management, and Rybelsus as a daily oral tablet. The trials compared the molecules themselves, so everything on this page applies whichever name is on the pen — and to the compounded versions telehealth providers sell, which contain the same active molecule at pharmacy-stated strengths. (Handling a compounded vial rather than a pen? The tirzepatide dosage calculator and semaglutide dosage calculator do the milligrams-to-units arithmetic.)

That is the strongest form of evidence available for a "which is better" question, and it removes most of the guesswork. What it does not remove is everything the trials were not designed to measure — and for a reader buying through telehealth, several of those things matter more than the headline.

What the Direct Comparison Found

The short version, and it is not controversial: in the head-to-head setting, tirzepatide produced greater weight reduction and greater glycemic improvement than semaglutide. SURPASS-2 was designed as a direct comparison in type 2 diabetes and reported tirzepatide's advantage across its doses¹.

The obesity comparison tells a consistent story. SURMOUNT-5's published post hoc analysis examined the relationship of early rapid weight loss to the efficacy and safety of both drugs, treating them as the two arms of one trial rather than two separate literatures².

Each drug also has its own foundational obesity evidence to sit alongside that. Semaglutide's is the STEP program, with STEP 1 establishing substantial sustained weight loss over 68 weeks³ across a broader trial series⁴. Tirzepatide's is SURMOUNT-1⁵, with later work extending into diabetes prevention⁶.

So on the primary endpoint the trials were built to measure, the answer is clear. Now the parts that are not in the headline.

Difference One: They Are Not the Same Kind of Drug

Semaglutide is a 31-amino-acid peptide that activates one receptor, GLP-1⁷. Tirzepatide is a 39-amino-acid peptide that activates two — GIP as well as GLP-1 — which is why it is described as a dual agonist rather than a GLP-1 agonist.

That is a genuine pharmacological difference rather than a marketing one, and it is the most likely explanation for the efficacy gap. It also means the two drugs are not interchangeable in the way "they're both GLP-1s" implies. A provider that will not name which molecule you are receiving is not offering you a choice between similar things.

Difference Two: The Labeling Differs on Pregnancy and Contraception

This is the difference that changes decisions most often and appears in comparisons least often.

The labeled instructions are not the same between these two molecules on contraception and pregnancy planning. The contraceptive instruction attaches to tirzepatide and not to semaglutide — a difference that exists in the approved labeling, not in anyone's interpretation of it.

For anyone who could become pregnant, that turns "which is more effective" into a second question that the efficacy data cannot answer. It is the ranking criterion on best weight loss peptides for women, and we cover the underlying evidence base in peptides for women and the transition-specific version in peptides for menopause.

Difference Three: What You Lose Is Not All Fat

A substantial share of the weight lost on either drug is lean tissue rather than fat, and the proportion is not identical between them. This is the most under-discussed fact in the category and it does not appear on any provider's comparison table.

It matters practically: two people losing the same number on the scale can have meaningfully different outcomes depending on what the loss was made of. We set out the numbers in semaglutide, tirzepatide and muscle loss, and the mitigation — resistance training and adequate protein alongside, not instead of — in peptides for weight loss and muscle gain.

Difference Four: The Trials Studied the Approved Products

Here is the gap between the evidence and the purchase, and it is the one this site exists to cover.

The trials above studied the approved, manufactured products. A compounded version — the same molecule, made by a compounding pharmacy rather than the manufacturer — is a different product with a different regulatory position, and that position has moved more than once. If that is what you are buying, and on the desks we track it frequently is, the distinction is yours to carry. See is compounded semaglutide or tirzepatide still legal and the peptide FDA status tracker.

The practical consequence is that the trial results tell you about the molecules, and tell you nothing about the vial. Which is why what a specific provider actually sells, at what real price, is a separate investigation.

What the Two Cost, Which Is Rarely What Is Advertised

Tirzepatide is generally the more expensive of the two across the desks we track, which turns the efficacy comparison into a real trade rather than an obvious choice. But the advertised figures are frequently a term rather than a price, and that distorts the comparison before it starts.

SkinnyRx publishes four terms for every product it sells: injectable semaglutide is $349 monthly, $299 on four months, $249 on six and $199 only on twelve; injectable tirzepatide runs $399, $349, $329 and $299 the same way. Every tile on the site says "As low as $199/mo" — the twelve-month rung. That is more structure than most desks publish, advertised as though it were one number.

Rivo Health's $149 semaglutide and $199 tirzepatide are Spring-sale rates, with the deepest discounts requiring six months. Care Bare Rx names injectable and oral tirzepatide and semaglutide as confirmed products and publishes a price for none of them — the only figure is a category-wide "From $199/mo" floor. LaSara charges $299 for one month of semaglutide and $399 for one month of tirzepatide on its live product pages, while its own marketing page still advertises "starting at $179". HealthRX publishes the whole ladder with prepay marked optional, which is what a fair page looks like.

The boards do this row by row: best tirzepatide providers, best semaglutide providers, and cheapest tirzepatide online, where every figure is labeled with the commitment that unlocks it. The full dataset is the price transparency index.

Side Effects: Same Family, Different Intensity

The tolerability comparison is the one people ask about second and it is worth handling carefully, because the honest answer is more nuanced than either "tirzepatide is worse" or "they're the same".

Both drugs share the class's dose-limiting problem: gastrointestinal effects — nausea, vomiting, diarrhea, constipation — concentrated during dose escalation and generally easing as tolerance develops. That is why both titrate slowly rather than starting at a target dose, and why the trial results everyone quotes were produced under a schedule rather than in spite of one.

Two things follow that matter for a reader choosing.

Intensity tends to track effect. The drug producing more weight reduction is generally not the gentler one, which makes the comparison a genuine trade rather than a free upgrade. Someone who tolerates semaglutide comfortably is not obviously better off switching.

Titration is the lever, not the molecule. Most tolerability problems in this class are managed by slowing the ladder rather than by changing drug, which is a conversation with a prescriber rather than a reason to switch providers. We cover the arithmetic side of that in tirzepatide dosage and the deliberate-low-dose practice in microdosing tirzepatide.

Switching Between Them

A common real-world question, and one the trials do not directly answer: the head-to-head studies randomized people to one drug or the other, not from one to the other.

What that means practically is that switching is a clinical decision with no trial to point at, and the sensible framing is that you are starting a new drug rather than continuing an old one — which usually means re-entering a titration rather than matching your previous dose. The molecules are not equivalent milligram for milligram; a dose on one does not translate to a dose on the other, and treating them as convertible is the same category error as copying a syringe unit number between differently mixed vials.

Where Retatrutide Fits

The obvious follow-on question. Retatrutide adds a third receptor and has Phase 2 obesity data⁸, but it is investigational — no approved product, anywhere, for any indication. It is not a third option in the same sense; it is a compound still being tested that is nonetheless being sold. See retatrutide vs tirzepatide and retatrutide side effects.

Bottom Line

On the question the trials were designed to answer, tirzepatide won: the direct head-to-head comparison in type 2 diabetes found greater weight and glycemic improvement than semaglutide¹, and the obesity head-to-head program is consistent². Both have strong independent obesity evidence of their own³⁴⁵⁶.

But "more effective" is one input among several, and the other four are not in the trial data:

• •They are pharmacologically different — one receptor versus two⁷ — so they are not interchangeable.
• •The labeling differs on contraception and pregnancy planning, which for anyone who could become pregnant is a decision the efficacy numbers cannot make.
• •A share of the loss is lean tissue on both, and not in the same proportion.
• •A compounded version is not the product that was tested, and its regulatory position has moved more than once.

If you are choosing, the honest sequence is: settle the molecule question with a clinician on the labeling and your own circumstances, then compare providers on the real month-to-month price rather than the advertised one. Start at the rankings index.